PubAg

Main content area

Establishment of TP53-knockout canine cells using optimized CRIPSR/Cas9 vector system for canine cancer research

Author:
Eun, Kiyoung, Park, Min Gi, Jeong, Yeon Woo, Jeong, Yeon Ik, Hyun, Sang-Hwan, Hwang, Woo Suk, Kim, Sung-Hak, Kim, Hyunggee
Source:
BMC biotechnology 2019 v.19 no.1 pp. 1
ISSN:
1472-6750
Subject:
RNA, antineoplastic agents, clones, disease models, dogs, gene editing, gene targeting, genomics, genotoxicity, loci, longevity, mutation, neoplasms, nuclear transplantation, phenotype, transfection, tumor suppressor genes
Abstract:
BACKGROUND: Genetic engineering technology such as clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system provides a powerful tool for developing disease models and determining gene functions. Recent interests in canine cancer models have highlighted the necessity of developing genetic engineering tools for dogs. In this study, we attempted to generate optimized CRISPR/Cas9 system to target canine tumor protein 53 (TP53), one of the most crucial tumor suppressor genes, to establish TP53 knockout canine cells for canine cancer research. RESULTS: We constructed CRISPR/Cas9 vectors using each of three TP53 gene-targeting guide RNAs (gRNAs) with minimal off-target potential. After transfection, we obtained several clones of TP53 knockout cells containing “indel” mutations in the targeted locus which had infinite cellular life span, resistance to genotoxicity, and unstable genomic status in contrast to normal cells. Of the established TP53 knockout cells, TP53KO#30 cells targeted by TP53 gRNA #30 showed non-cancerous phenotypes without oncogenic activation both in vitro and in vivo. More importantly, no off-target alteration was detected in TP53KO#30 cells. We also tested the developmental capacity of TP53 knockout cells after application of the somatic cell nuclear transfer technique. CONCLUSIONS: Our results indicated that TP53 in canine cells was effectively and specifically targeted by our CRISPR/Cas9 system. Thus, we suggest our CRISPR/Cas9-derived canine TP53 knockout cells as a useful platform to reveal novel oncogenic functions and effects of developing anti-cancer therapeutics.
Agid:
6276117